Muhammad Akbar Ramadhan Munandar et al. 2026. Cost-Effectiveness of Pembrolizumab as First-Line Treatment for PD-L1 Positive NSCLC: A Systematic Review. The International Journal of Medical Science and Health Research. 23, 2 (Jan. 2026), 64–130. DOI:https://doi.org/10.70070/h3zdy035.